# A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis

> **NCT02427776** · PHASE1,PHASE2 · TERMINATED · sponsor: **Imcyse SA** · enrollment: 2 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **BIOLOGICAL:** Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope

## Key facts

- **NCT ID:** NCT02427776
- **Lead sponsor:** Imcyse SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** study ended prior enrollment of the first patient because of unexpected issues in the manufacturing process prevented production of adequate clinical batches
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02427776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02427776, "A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02427776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*